1-13 of 13
gem trial
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Free
Pieter Sonneveld, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Thierry Facon, MD, Cyrille Hulin, MD, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, MD, Sarah Cote, Philippe Moreau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4739.
https://doi.org/10.1182/blood-2019-122775
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Free
Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Free
Laura Rosinol Dachs, Albert Oriol, MD, Ana Isabel Teruel, MDcal Doctor, Ana López de la Guía, M Jesús Blanchard, Isidro Jarque, Miquel Granell, MD, Antonia Sampol, Luis Palomera, MD PhD, Yolanda Gonzalez-Montes, Enrique Bengoechea, Rafael Martínez-Martínez, Miguel T Hernández, MD PhD, Felipe De Arriba, PhD, Maria Luisa Martin-Ramos, Norma C. Gutierrez, MD PhD, Maria Teresa Cibeira, MD PhD, Maria-Victoria Mateos, MD PhD, Joaquin Martinez-Lopez, MD PhD, Adrián Alegre, MD, Juan Jose Lahuerta, MD PhD, Jesus F San-Miguel, MD PhD, Joan Blade, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 126.
https://doi.org/10.1182/blood-2018-99-111924
Published: 2018
Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Free
Laura Rosinol, MD PhD, Albert Oriol, MD, Rafael Rios, Anna Sureda, MD PhD, M Jesús Blanchard, Miguel T Hernández, Rafael Martínez-Martínez, Jose M Moraleda, Isidro Jarque, Juan Bargay, Mercedes Gironella, Dra., Maria José Moreno, Luis Palomera, Yolanda Gonzalez-Montes, Josep M Marti, Isabel Krsnik, Jose M Arguiñano, Maria Esther González, Ana Pilar González, Felipe Casado, Lucía Lopez-Anglada, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Jesus F. San Miguel, MD, Juan-José Lahuerta, Joan Blade, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2017.
https://doi.org/10.1182/blood.V130.Suppl_1.2017.2017
Published: 2017
Journal Articles

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Free
Laura Rosiñol, MD PhD, Albert Oriol, MD, Ana Isabel Teruel, MD, Dolores Hernandez, M Jesús Blanchard, Javier De La Rubia, Miquel Granell, MD, Juan Besalduch, MD PhD, Luis Palomera, Yolanda Gonzalez, M Asunción Echebeste, Joaquín Díaz-Mediavilla, Miguel T Hernandez, MD, Felipe de Arriba, Norma Carmen Gutierrez, PhD MD, M Luisa Martín-Ramos, M Teresa Cibeira, Maria Victoria Mateos, Joaquin Martinez-Lopez, MD PhD, Adrian Alegre, MD, Juan José Lahuerta, MD PhD, Jesus F. San Miguel, Joan Blade
Journal: Blood
Blood (2014) 124 (21): 3457.
https://doi.org/10.1182/blood.V124.21.3457.3457
Published: 2014
Journal Articles

Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)

Free
Laura Rosiñol, MD, Raquel Jiménez-Segura, Ana Isabel Teruel, MD, Javier De La Rubia, MD, PhD, Maria Victoria Mateos, MD, PhD, Miguel T. Hernandez, Dolores Hernández, M Jesús Blanchard, Belén Iñigo, Luis Palomera, MD, Isabel Krsnik, MD, PhD, Jose Francisco Tomas, MD, Norma C. Gutiérrez, Jesús F. San Miguel, MD, PhD, Juan José Lahuerta, Joan Blade, MD
Journal: Blood
Blood (2013) 122 (21): 3188.
https://doi.org/10.1182/blood.V122.21.3188.3188
Published: 2013
Journal Articles

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Free
Clinical Trials & Observations
Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, Javier López-Jiménez, Javier de la Rubia, Miquel Granell, Joan Besalduch, Luis Palomera, Yolanda González, Mª Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T. Hernández, Felipe de Arriba, Norma C. Gutiérrez, Mª Luisa Martín-Ramos, Mª Teresa Cibeira, Mª Victoria Mateos, Joaquín Martínez, Adrián Alegre, Juan José Lahuerta, Jesús San Miguel, Joan Bladé
Journal: Blood
Blood (2012) 120 (8): 1589–1596.
https://doi.org/10.1182/blood-2012-02-408922
Published: 2012
Includes: Supplemental data
Journal Articles

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Free
Laura Rosiñol, María Teresa Cibeira, MD, PhD, Maria Victoria Mateos, MD, Joaquin Martinez, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, José García-Laraña, Javier De La Rubia, Anna Sureda, MD, PhD, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, Maria Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T. Hernández, Felipe de Arriba, Adrian Alegre, Juan José Lahuerta, Jesus F San Miguel, Joan Blade
Journal: Blood
Blood (2010) 116 (21): 307.
https://doi.org/10.1182/blood.V116.21.307.307
Published: 2010
Journal Articles

Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade) â /Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade â as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.

Free
Laura Rosiñol, Ma Teresa Cibeira, Joaquin Martinez, Maria Victoria Mateos, Albert Oriol, Ma José Terol, Jose García-Laraña, Dolores Hernández, Javier de la Rubia, Anna Sureda, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, Ma Asuncion Echebeste, Joaquin Díaz-Mediavilla, Felipe de Arriba, Adrian Alegre, Miguel T Hernández, Juan José Lahuerta, J.F F San Miguel, Joan Blade
Journal: Blood
Blood (2009) 114 (22): 130.
https://doi.org/10.1182/blood.V114.22.130.130
Published: 2009
Journal Articles

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

Free
Laura Rosinol, M. Teresa Cibeira, Joaquin Martinez, Maria Victoria Mateos, Ma José Terol, Javier de la Rubia, Luis Palomera, Felipe de Arriba, Albert Oriol, Adrian Alegre, Juan Besalduch, Raquel de Paz, José Garcia-Laraña, Joaquín Díaz-Mediavilla, Anna Sureda, Juan José Lahuerta, J.F. San Miguel, Joan Blade
Journal: Blood
Blood (2008) 112 (11): 654.
https://doi.org/10.1182/blood.V112.11.654.654
Published: 2008
Journal Articles

Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.

Free
Joan Blade, MD, Laura Rosinol, MD, Juan Jose Lahuerta, MD, Anna Sureda, MD, Javier de la Rubia, MD, Jose Garcia-Larana, MD, Miguel Hernandez-Garcia, MD, Belen Hernandez-Ruiz, MD, Jose Antonio Perez-Simon, MD, Jose Luis Bello, MD, Dolores Carrera, MD, Maria Jesus Penarrubia, MD, Eugenia Abella, MD, Angel Leon, MD, Concepcion Poderos, MD, Juan Carlos Garcia-Ruiz, MD, Joan Besalduch, MD, Rafael Martinez-Martinez, MD, Isabel Perez-Fernandez, MD, Paz Ribas, MD, Jesus San Miguel, MD
Journal: Blood
Blood (2007) 110 (11): 729.
https://doi.org/10.1182/blood.V110.11.729.729
Published: 2007
Journal Articles

Feasibility and Efficacy of a Planned Second Transplant (“auto” or “mini-allo”) Intensification in Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.

Free
L. Rosiñol, J. J. Lahuerta, A. Sureda, J. de la Rubia, J. García-Laraña, M. Hernández-García, B. Hernández-Ruíz, J. A. Pérez-Simón, J. L. Bello, D. Carrera, M. J. Peñarrubia, E. Abella, A. León, C. Poderós, J. C. García-Ruíz, J. Besalduch, R. Martínez-Martínez, I. Pérez-Fernández, P. Ribas, F. Escalante, J. San Miguel, J. Bladé.
Journal: Blood
Blood (2005) 106 (11): 425.
https://doi.org/10.1182/blood.V106.11.425.425
Published: 2005
Journal Articles

High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.

Free
L. Rosinol, R. Garcia-Sanz, J. J. Lahuerta, M. Hernandez-Garcia, A. Sureda, J. de la Rubia, J. M. Ribera, B. Hernandez-Ruiz, D. Carreras, I. Navarro, J. C. Garcia-Ruiz, S. Gardella, J. Garcia-Larana, J. Diaz-Mediavilla, J. F. San Miguel, J. Blade
Journal: Blood
Blood (2005) 106 (11): 5472.
https://doi.org/10.1182/blood.V106.11.5472.5472
Published: 2005